Integrated DNA Technologies announces translational CRISPR portfolio expansion
Integrated DNA Technologies (IDT) has revealed new additions to its end-to-end CRISPR portfolio.
These expanded CRISPR translational research solutions are designed to help researchers accelerate more CRISPR-based therapies for patients like KJ Muldoon, an infant who suffered CPS1 deficiency and made history when he received the world’s first personalized CRISPR therapy manufactured jointly by IDT and Aldevron. IDT provided the guide RNA (gRNA), off-target analysis services and regulatory support for baby KJ’s treatment, which was delivered in a significantly compressed timeline.
As researchers advance from discovery to clinical applications, the demand for higher purity in CRISPR reagents increases. To meet this need, IDT’s chemically synthesized gRNAs are now available for online ordering in a range of modification and purity options. With high purity ideal for translational applications such as gene editing in primary cells and in vivo models, IDT’s high-performance liquid chromatography (HPLC)-purified gRNAs are orderable in 2 nmol and 10 nmol yields with larger quantities available by request and ship in as little as 12 business days. Formats include CRISPR-Cas9 gRNA and Custom Alt-R CRISPR gRNA. 2’ Fluoro, 2’ O-Methyl, and other modifications can be added to increase stability and specificity with IDT’s custom gRNA tool.
CRISPR-based genome editing allows for targeted editing at specific sites in the genome, but there is potential risk that off-target edits at other locations can occur. To enable scientists to understand where these off-target edits might happen and assess how they might impact safety early in the therapeutic development process, IDT launched UNCOVERseq, off-target nomination services which uses an enhanced GUIDE-seq methodology to identify off-target sites for its customers. When paired with IDT’s award-winning off-target confirmation services, rhAmpSeq CRISPR Analysis System, CRISPR pioneers can confidently accelerate their path to the clinic by obtaining a deeper understanding of editing risks.
